Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

• Status: Unknown status
• Trial end date: 2018-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in non-small cell lung cancer patients harboring uncommon EGFR mutation

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences

Criteria

Inclusion Criteria:

• Patients with stage IIIB/IV non-small cell lung cancer

• Patients with uncommon epidermal growth factor receptor (EGFR) mutation

• Targeted-therapy-naive patients

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

• Evaluable target lesions according to RECIST 1.1 for tumour response assessment

Exclusion Criteria:

• Wild-type EGFR

• Positive 19 del and/or 21 L858R mutation

• Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib

• Patients who have documented history of interstitial lung disease